Latest 8-K filings

Longeveron Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.

Dave & Buster's announced its second quarter 2026 financial results, reporting a decrease in revenue and a net loss, though management highlighted strategic momentum.

Rare Element Resources Ltd. announced the appointment of Josef Bilant as Chief Operating Officer, effective October 5, 2026, bringing extensive experience in mineral and mining operations.

PDS Biotechnology Corporation announced the initial closing of an $11.3 million PIPE financing and the appointment of Dr. Patrick Soon-Shiong to its Board of Directors, signaling strategic investment and leadership enhancement.

Magnolia Oil & Gas Corporation has successfully closed its acquisition of WildFire Energy I LLC, integrating its assets and operations.

First Citizens BancShares, Inc. has filed a Certificate of Designation to establish its 7.500% Non-Cumulative Perpetual Preferred Stock, Series F, and has closed a public offering of 300,000 depositary shares representing interests in this new series.

Sionna Therapeutics announces a significant restructuring, including a 46% workforce reduction and discontinuation of the SION-719 program, to focus resources on its SION-451 and SION-2222 dual combination for cystic fibrosis.

Burford Capital Limited announces a $300 million private offering of senior secured notes due 2029 and plans to redeem its outstanding $400 million of 6.250% senior notes due 2028.

Boot Barn Holdings, Inc. announced participation in upcoming investor conferences and provided a positive business update, expecting second fiscal quarter sales and earnings per share to reach the high end of previously issued guidance.

Veracyte, Inc. has acquired Convergent Genomics, bolstering its urology diagnostics portfolio with Convergent's urinary tumor DNA testing platform.

Contineum Therapeutics announced that its Phase 2 MOONLIGHT-1 trial for JNJ-5120/PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint.

Teva Pharmaceutical Industries Ltd. has transitioned its ordinary shares to trade directly on the New York Stock Exchange, replacing its American Depositary Shares (ADSs) program.

Oxford Square Capital Corp. announced its intention to redeem $15 million of its 5.50% Notes due 2028, with the redemption date set for October 14, 2026.

60 Degrees Pharmaceuticals has submitted a request for a Commissioners National Priority Voucher for its babesiosis treatment, ARAKODA, aiming for potential early FDA approval.

Parker-Hannifin Corporation has successfully closed registered offerings for $2.4 billion in U.S. dollar-denominated senior notes and €2.025 billion in Euro-denominated senior notes.

INmune Bio Inc. has appointed two experienced biopharmaceutical leaders, R. Duane Clark II and James Sapirstein, to its Board of Directors to bolster commercialization and strategic partnering capabilities.

Vaxart, Inc. has implemented new policies requiring director resignations upon receiving more withhold than for votes and establishing stock ownership targets for non-employee directors.

Scienture Holdings, Inc. has posted a revised investor presentation to its website, signaling ongoing engagement with analysts and potential investors.

Lesaka Technologies announced adjustments to its Group Chief Financial Officer's base salary and introduced new cash incentive awards for fiscal year 2027 for key executives, linking compensation to performance metrics.

NextNRG, Inc. has filed a Form 8-K announcing a 1-for-10 reverse stock split, effective September 14, 2026, to reduce outstanding shares.

Inseego Corp. announced the resignation of Board Director Stephen Bye, effective September 30, 2026, due to his appointment as CEO of WW International.

CPI Card Group Inc. announced a public offering of common stock by its selling stockholders, with the company not receiving any proceeds from the sale.

Benitec Biopharma announced fiscal year 2026 financial results, highlighting progress in its BB-301 clinical trial for OPMD and a robust cash reserve of $180 million.

Kestra Medical Technologies announced a 60% revenue increase and significant gross margin expansion in its first quarter of fiscal year 2027, while also raising full-year revenue guidance.

Elicio Therapeutics, Inc. has announced its 2026 annual meeting date and established deadlines for shareholder proposals and director nominations.

Emergent BioSolutions Inc. provided an update on its business, including restructuring efforts, financial performance, and strategic priorities at the H.C. Wainwright 28th Annual Global Investment Conference.

Yarrow Bioscience, Inc. has successfully completed a public offering of its common stock, raising approximately $161.8 million in net proceeds.

Kairos Pharma, Ltd. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, presenting an investor update on its clinical program.

Niki BioSolutions, Inc. (NIKI) has filed an 8-K detailing its corporate PowerPoint presentation, outlining the completion of its merger with Aptorum Group and its subsidiary DiamiR Biosciences, and presenting its strategic vision focused on Alzheimer's disease diagnostics and therapeutics.

Moleculin Biotech announced new data on its lead drug candidate, Annamycin, will be presented at three scientific conferences in September 2026, focusing on its concentration, mechanism, and potential immune system involvement.